Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial .Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation ...

Shares of Amgen (AMGN) fell by more than 5% on Wednesday after it reported top-line data on two different drugs in the autoimmune disease space. While the studies did meet their respective primary endpoints, Wall Street termed the results ‘lackluster’ and ‘underwhelming’.At a conference call on Tuesday, Amgen posted top-line data from two late-stage studies — HORIZON and MINT. The HORIZON study evaluated an investigational anti-OX40 therapy rocatinlimab in atopic dermatitis (AD or eczema) indication. In the ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.Shares of Amgen (NASDAQ: AMGN ) are down this week despite two positive ...

In an investor update on Tuesday, Amgen Inc AMGN released data from Phase 3 trials of rocatinlimab and Uplizna (inebilizumab).HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients.Amgen reported that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.Amgen stock is trading lower as the data seemed to be below expectations.Goldman Sachs notes that although the Phase 3 efficacy data for rocatinlimab is less compelling compared to Dupixent ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) is a leading biotechnology company based in Tarrytown, New York. REGN develops therapies for eye diseases, cancer, allergic conditions, and infectious diseases. Its portfolio contains commercial Eylea, Dupixent, and Libtayo that address critical medical needs andMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from ...

Shares of Regeneron Pharmaceuticals, Inc. (REGN) were down 4.63% after an unfavorable ruling in its lawsuit against Amgen (AMGN) in the United States District Court for the Northern District of West Virginia.The lawsuit was related to a biosimilar of its lead drug Eylea (aflibercept 2 mg).Regeneron’s shares have rallied 24.3% year to date against the industry’s decline of 1.5%.Image Source: Zacks Investment ResearchREGN’s Lawsuit Against AMGNEylea, REGN’s lead drug, is approved for various retinal condition ...

Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.It's hard to overstate just how successful weight-management treatments have been over the past couple of years. Sales of semaglutide, the drug that Novo Nordisk (NVO -2.99%) markets as Ozempic and Rybelsus for diabetes, and as Wegovy for weight management, have soared to an annualized $27.9 billion.Semaglutide first earned approval from the Food and Drug Administration (FDA) back in 2017. A much younger treatme ...

Amgen (AMGN) closed at $335.61 in the latest trading session, marking a -0.52% move from the prior day. This change lagged the S&P 500's daily gain of 0.28%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.15%.Shares of the world's largest biotech drugmaker witnessed a gain of 2.61% over the previous month, beating the performance of the Medical sector with its gain of 0.38% and the S&P 500's gain of 2%.Market participants will be closely following the financial results of Amgen in its ...

These two stocks could be rivals in the intense GLP-1 space in the future.Investing into companies involved with new weight loss medications can be overwhelming. There is a lot of competition in the space given the potential for the anti-obesity market to grow to a size of $100 billion or more, as per estimates from Goldman Sachs.The challenge becomes the following: Do you invest in an established healthcare company that is expanding into this new category of glucagon-like peptide-1 (GLP-1) medications, or ...

Company Performance - Amgen's stock closed at $332.80, reflecting a -0.73% change from the previous day's closing price, underperforming the S&P 500 which gained 0.03% [1] - Over the past month, Amgen's shares increased by 2.22%, while the Medical sector rose by 2.67% and the S&P 500 by 1.54% [1] - The upcoming earnings report is anticipated to show an EPS of $5.13, a 3.43% increase year-over-year, and revenue of $8.51 billion, indicating a 23.24% increase compared to the same quarter last year [1] Annual Estimates - For the annual period, earnings are projected at $19.49 per share and revenue at $33.21 billion, representing increases of +4.5% and +17.82% respectively from the previous year [2] Analyst Estimates and Valuation - Recent changes in analyst estimates for Amgen indicate a dynamic business outlook, with positive revisions suggesting optimism [2] - Amgen currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 0.06% in the last 30 days [3] - The company is trading at a Forward P/E ratio of 17.2, which is lower than the industry average of 23.02, and has a PEG ratio of 2.98 compared to the industry average of 2.28 [3] Industry Context - The Medical - Biomedical and Genetics industry, to which Amgen belongs, has a Zacks Industry Rank of 79, placing it in the top 32% of over 250 industries [3] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]